Page **1** of **19**

1 Assessment and clinical utility of a non-Next-Generation Sequencing based Non-

2 Invasive Prenatal Testing technology

- 3
- 4 Running title: Assessment and clinical utility of a non-NGS based NIPT technology
- 5
- 6 U Gormus¹, A Chaubey^{2,3}, S Shenoy², YW Wong⁴, LY Chan⁴, BP Choo⁴, L Oraha¹, A
- 7 Gousseva⁵, F Persson⁵, L Prensky⁶, E Chin² and M Hegde²
- ¹PerkinElmer Genomics Sweden, Sollentuna, Sweden; ²PerkinElmer Genomics, Pittsburgh,
- 9 USA; ³Bionano Genomics, San Diego, USA; ⁴DNA LAB, PerkinElmer Genomics Malaysia,
- 10 Selangor, Malaysia; ⁵Vanadis Diagnostics, PerkinElmer Inc, Sollentuna, Sweden;
- ¹¹ ⁶PerkinElmer Inc, Waltham, USA Corresponding author.
- 12 Lawrence.Prensky@Perkinelmer.com
- 13

Page **2** of **19**

14 Abstract:

15	Background: Rolling circle replication (RCR) is a novel technology that has not been
16	applied to cell-free DNA (cfDNA) testing until recently. Given the cost and simplicity
17	advantages of this technology compared to other platforms currently used in cfDNA analysis,
18	an assessment of RCR in clinical laboratories was performed. Here, we present the first
19	validation study from clinical laboratories utilizing RCR technology.
20	
21	Methods: 831 samples from spontaneously pregnant women carrying a singleton fetus and
22	25 synthetic samples were analyzed for the fetal risk of Trisomy 21, Trisomy 18 and Trisomy
23	13 by three laboratories on three continents. All women who provided the samples were
24	followed to birth, where evaluation for fetal aneuploidies was performed using newborn
25	examinations and any suspected aneuploidies were confirmed with karyotyping.
26	
27	Results : The study found rolling circle replication to be a highly viable technology for
28	clinical assessment of fetal aneuploidies with 100% sensitivity for T21 (95% CI:82.35% -
29	100.00%); 100.00% sensitivity for T18 (71.51% - 100.00%) and 100.00% sensitivity for T13
30	analyses (66.37% - 100.00%). The specificities were >99% for each trisomies [99.7%
31	(99.01% - 99.97%) for T21; 99.5% (98.62% - 99.85%) for T18; 99.7% (99.03% - 99.97%)

for T13], along with a first pass no-call rate of 0.93%.

33

34 Conclusions: The study showed that using a rolling circle replication-based cfDNA system
35 for the evaluation of the common aneuploidies would provide greater accuracy and clinical
36 utility compared to conventional biochemical screening and comparable results to other
37 reported cfDNA methodologies.

Page 3 of 19

Keywords: cell free DNA; noninvasive prenatal screening; noninvasive prenatal testing;
NIPT; NIPS; validation study; rolling circle replication; digital quantification; Prenatal
screening; Aneuploidy

41

42 INTRODUCTION

43 Trisomies are important chromosomal aberrations often associated with varying degrees of 44 intellectual disabilities, several health and developmental defects, and whose incidence is 45 correlated with increasing maternal age[1]. Although the average maternal age has increased 46 globally in the last 50 years, the incidence of trisomy has significantly decreased during that 47 time frame due to the increased utilization of improved prenatal screening tests[2]. 48 Historically, these prenatal screening tests consisted of biochemical blood tests and/or 49 ultrasound scans. These conventional screening tests are still used globally, but due to their 50 higher false positive rates and lower detection rates, they have started to be replaced by 51 newer, more accurate technologies using the placental cell-free DNA (cfDNA) circulating in 52 the maternal blood. Cell-free nucleic acids, also known as extracellular nucleic acids, are 53 fragments of DNA or RNA molecules that are released from cells into the body fluids.

54 Lo et al were the first to report that a portion of the cell-free DNA in maternal blood was 55 from the fetus and placenta and to comment on how cell-free fetal DNA was suitable for 56 prenatal examinations[3]. The introduction of cell-free DNA into prenatal clinical practice 57 first started through the use of next-generation sequencing (NGS) technology for the 58 assessment of Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy 13 (T13), and was referred 59 to as Non-Invasive Prenatal Testing (NIPT)[4,5]. Although NIPT has been shown to be 60 highly accurate, the next generation sequencing techniques that were used has limited the 61 global accessibility to this test due to its high cost and complexity. It has been noted that a 62 considerable cost reduction is necessary to make this approach cost effective enough to be

Page **4** of **19**

63	commonly used[6]. Furthermore, the complexity of the NGS-based technologies adds
64	additional hurdles to the ability of laboratories to implement this test. Vanadis® NIPT was
65	developed without using NGS or polymerase chain reaction (PCR), to enable a cost effective
66	and high performance cfDNA aneuploidy screening.
67	Vanadis [®] NIPT is a new technology targeting relevant chromosomes based on a digital
68	molecular quantification in a 960 well microplate[7,8]. The method converts targeted
69	chromosomal fragments into digitally quantifiable objects through rolling circle replication
70	and chromosome-specific labeling. The normalized ratio between the number of chromosome
71	specific objects are then used to calculate the z-score which is mapped to a post-test risk.
72	Here, we report on the clinical performance of the Vanadis® NIPT assay in PerkinElmer
73	Genomics Laboratories.

74

75 MATERIALS AND METHOD

76 **Ethics Statement:**

Protocols used for sample collection were approved by the Research Ethics Board of CHU de
Québec (#2016-2989 and #2020-4895). The study was performed in accordance with the
ethical standards of the institutional and/or national research committees.

80 Study Population and Clinical Evaluation:

Validation protocols were written based upon templates relevant to the Vanadis system (Supplemental A and B). Based on this, a total aggregated set of 831 samples from spontaneously pregnant women carrying a singleton fetus were analyzed. The inclusion criteria for participation in this study were pregnant women between the ages of 18 and 50

Page 5 of 19

85	and between 10 and 40 gestational weeks. The women were not selected based on prior risk
86	and all consented to participate in the study. All subjects were followed to birth, where
87	evaluation for fetal aneuploidies was performed using newborn examinations and any
88	suspected aneuploidies were confirmed with karyotyping. 10 milliliters (mL) of blood were
89	collected from each woman between February 2019 and July 2019 at maternity clinics in
90	Kuala Lumpur and Quebec. Blood samples were processed as described below, and at least 3
91	mL of plasma was extracted and sent to PerkinElmer Genomics (PKIG) labs located in
92	Sollentuna, Sweden; Kuala Lumpur, Malaysia; and Pittsburgh, USA.

Ten samples from confirmed T21 positive pregnancies and three samples from confirmed T18 positive pregnancies and one sample from a confirmed T13 pregnancy were used. Other trisomy positive control samples (nine of T21, eight of T18 and eight of T13) were purchased from SeraCare Life Sciences, Inc. (USA) (Seraseq Trisomy 21 aneuploidy reference material-0720-0019, Trisomy 13 aneuploidy reference material- 0720-0017, Trisomy 18 aneuploidy reference material- 0720-0018).

99

100 Sample collection and preparation:

Blood samples were collected into Cell-FreeTM DNA BCT tubes (Streck, Omaha, USA)
from each pregnant woman. After arrival in the lab by courier, study samples were barcoded
with unique subject codes and patient identification numbers and anonymized.

Samples were processed in the PKIG lab in Kuala Lumpur and the CHU de Québec-Université Laval lab in Quebec by using a double centrifugation protocol[8]. All plasma was separated within 5 days of blood draw and stored in new plasma storage tubes. The plasma tubes were barcoded with unique subject codes and patient identification numbers were anonymized. The plasma tubes were stored at -80°C until processing at a PKIG Laboratory.

Page 6 of 19

```
109
```

110 Test method:

Samples were analyzed using the Vanadis[®] system following existing manuals and 111 instructions for use. The Vanadis[®] NIPT assay uses a series of enzymatic steps to generate 112 113 labelled rolling circle replication products (RCPs) from chromosomal cfDNA targets, as 114 previously described[7]. Automated extraction of cfDNA from plasma was performed using the Vanadis Extract[®] platform, followed by continued processing on the Vanadis Core[®] 115 platform to generate labelled RCPs, which were then imaged and counted using the Vanadis 116 View[®] instrument. The performance metrics to be evaluated were based on the Z-score 117 results were calculated with LifecycleTM software version 7.2 and exported to an Excel file. 118

119

120 Data Analysis and Sample Classification:

121 Automated data analysis and quality assessment were performed, and chromosomal ratio 122 calculations were calculated for all approved samples. The results were classified into low or 123 high risk with a $Z \square$ score approach based on each normalized chromosomal ratio and the 124 sample specific standard deviation. The Z-score cut-off values were 3.5 for chromosome 21 125 and 3.15 for chromosomes 18 and 13. The samples that failed the quality assessment were 126 rejected and classified as 'no call'. The fetal sex was classified from the number of detected 127 RCPs from chromosome Y relative to the number of RCPs from the measured autosomal 128 chromosomes using an adaptive binary classifier [7,8]. Measured fetal fraction, which is 129 often thought to be a useful quality control metric, was not gathered as recent studies have 130 shown that it can be significantly incorrect[9].

131

132 **RESULTS**

Page **7** of **19**

133	A total of 856 samples (Figure 1) were included in the study, 831 of them were taken from
134	singleton pregnancies with spontaneous fertilization and 25 were reference material provided
135	by SeraCare Life Sciences, Inc. (USA). There were eight first pass no call results that were
136	excluded from calculations (first pass no call rate: 0.93%). The average median maternal age
137	in the study group was 32 (min:20 years, max: 46 years). The median gestational age was 12
138	weeks 5 days (min:10 weeks, max: 34 weeks).
139	The results from the test (Table 1) showed 100% sensitivity for T21 [95% Confidence
140	Interval (CI):82.35% - 100.00%]; 100.00% sensitivity for T18 (95% CI:71.51% - 100.00%)
141	and 100.00% sensitivity for T13 analyses (95% CI:66.37% - 100.00%). The specificities
142	were >99% for each trisomies [99.7% (95% CI: 99.01% - 99.97%) for T21; 99.5% (95%
143	CI:98.62% - 99.85%) for T18; 99.7% (95% CI:99.03% - 99.97%) for T13].
144	No false negative results were detected (FNR: 0%) with low levels of false positive rates
145	(FPR: 0.24% for T21, 0.47% for T18 and 0.24% for T13).
146	For fetal gender assessment, accuracy was 98.80% (Table 2). Of note, a recent blinded study
147	at an independent site using improved Y chromosome detection modifications in reagents and
148	analysis software showed 100% concordance for fetal sex determination between Vanadis

and NGS methods (n= 251 samples; unpublished observations).

150

151 **DISCUSSION**

Vanadis[®] NIPT is an efficient and cost-effective option for prenatal screening. The test can
be offered to pregnant women starting from the 10th week of gestation and can be integrated
as a first tier choice as prenatal screening analysis as it is more cost-effective than the NGS-

Page 8 of 19

based NIPT[10] and has a higher sensitivity and specificity compared to the conventionalbiochemical screening[11].

157 This study shows high sensitivity and specificity of Vanadis NIPT analysis. In this sample 158 set, all aneuploidy cases were detected accurately, thus resulting in a sensitivity of 100% for 159 trisomy 21, trisomy 18, and trisomy 13 and a \geq 99.5% specificity. Specificity would likely be 160 even higher if a second tube of blood was available for the samples with borderline Z-scores. 161 Furthermore, if a second sample was available for these patients, then the low first pass no 162 call rate of 0.93% would likely be reduced to a final no call rate of around 0.1%, based upon 163 a previous study showing a 87.5% reduction of no calls when a second sample is run on the 164 Vanadis[®] system[12].

165 Studies have shown that the sensitivity and specificity of NIPT are better than the 166 conventional screening methods [13-21] which has lead professional societies (such as the 167 American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal 168 Medicine) to state "Cell-free DNA is the most sensitive and specific screening test for the 169 common fetal aneuploidies"[11]. NIPT technologies that involve next generation sequencing 170 have shown that 98 - 100% of common aneuploidies can be detected at a combined false 171 positive rate of 0.44 - 0.91% [22]), while conventional biochemical screening can range from 172 50 - 95%, with a false positive rate of 5%, depending upon which screening strategy was 173 used[23]. By providing higher detection rates and lower false positive and negative rates 174 compared to conventional screening, NIPT technologies are more clinically effective and lead 175 to fewer invasive procedures[24].

As this study shows, the Vanadis[®] system provided results comparable to those of the more common NIPT technologies (Table 3). Both groups show similar sensitivities and specificities, which are greater than those for the conventional biochemical screening, thus

Page **9** of **19**

emphasizing their clinical utility. Although similar in performance, there is a difference when it comes to the technological complexity and cost-effectiveness. By removing the need for PCR and NGS, the installation, hands-on time, bioinformatics and run costs are automatically significantly lower with the Vanadis system. As has been reported, there is additionally a cost-savings for medical systems using this technology over sequencing from a follow-up point of view due to the lower no call rate[10].

Irrespective of the technology or methodology, there are some limitations to NIPT analysis which help to explain discrepancies between the test results and the fetal status. For example, since the cell-free fetal DNA is mainly produced by the placenta rather than fetus, false positive results can arise due to placental mosaicism[25-27] or the presence of a vanishing twin[28,29]. Additionally, false positive results or no call results may appear as a result of maternal cancer[30] or maternal chromosome anomalies[31]. Other limitations of the assay could arise from complex chromosomal abnormalities[26,32,33].

This study illustrates the high accuracy and clinical utility of Vanadis[®] NIPT compared to traditional prenatal screening methods for common aneuploidy. As an equally accurate and reliable NIPT test, Vanadis[®] NIPT can help eliminate the barrier to widespread usage of prenatal cfDNA for the global pregnancy population by being a technology that is significantly less complex to run and more cost effective.

197

198 ACKNOWLEDGEMENT

The authors would like to thank Professor Emmanuel Bujold and members of the Perinatal
Biobank of the CHU de Québec-Université Laval for their assistance in collecting and
preparing samples.

Page **10** of **19**

202

203 CONFLICT OF INTEREST

204 All authors are current or former employees of PerkinElmer Inc.

Page **11** of **19**

206 **REFERENCES**

- Carothers AD, Hecht CA, et al. International variation in reported livebirth
 prevalence rates of Down syndrome, adjusted for maternal age. J. Med. Genet.
 1999;36: 386–393.
- Huete-García A, Otaola-Barranquero M, Demographic Assessment of Down
 Syndrome: A Systematic Review. Int J Environ Res Public Health. 2021 Jan 5;18(1):
 352. doi: 10.3390/ijerph18010352.
- 213 3. Lo YM, Corbetta N, et al. Presence of fetal DNA in maternal plasma and serum.
 214 Lancet. 1997;350(9076): 485–7.
- Dondorp W, de Wert G, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet.
 2015 Nov;23(11): 1592. doi: 10.1038/ejhg.2015.109. Erratum for: Eur J Hum Genet.
 2015 Nov;23(11): 1438-50.
- Gil MM, Accurti V, et al. Analysis of cell-free DNA in maternal blood in screening
 for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017
 Sep;50(3):302-314. doi: 10.1002/uog.17484. Update in: Ultrasound Obstet Gynecol.
 2019 Jun;53(6): 734-742.
- Ayres AC, Whitty JA, et al. A cost-effectiveness analysis comparing different
 strategies to implement noninvasive prenatal testing into a Down syndrome screening
 program. Aust N Z J Obstet Gynaecol. 2014 Oct;54(5): 412-7. doi:
 10.1111/ajo.12223.
- Dahl F, Ericsson O, et al. Imaging single DNA molecules for high precision NIPT.
 Sci Rep. 2018 Mar 14;8(1): 4549. doi: 10.1038/s41598-018-22606-0.

Page **12** of **19**

229	8.	Ericsson O, Ahola T, et al. Clinical validation of a novel automated cell-free DNA
230		screening assay for trisomies 21, 13, and 18 in maternal plasma. Prenat Diagn. 2019
231		Oct;39(11): 1011-1015. doi: 10.1002/pd.5528.
232	9.	Persson F, Prensky L. Variability of "Reported Fetal Fraction" in Noninvasive
233		Prenatal Screening (NIPS). Clinical Chemistry. 2021 June;67(6): 863-866. doi:
234		10.1093/clinchem/hvab014
235	10	Huang T, Gibbons C, et al. Prenatal screening for trisomy 21: a comparative
236		performance and cost analysis of different screening strategies. BMC Pregnancy
237		Childbirth. 2020;20: 713.
238	11	American College of Obstetricians and Gynecologists' Committee on Practice
239		Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine.
240		Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number
241		226. Obstet Gynecol. 2020 Oct;136(4): e48-e69
242	12	Karlsson F, Ahola T, et al. Evaluation of repeat testing of a non-sequencing based
243		NIPT test on a Finnish general-risk population. Acta Obstet Gynecol Scand. 2021 Feb
244		11. doi: 10.1111/aogs.14125.
245	13	Chiu RW, Akolekar R, et al. Non invasive prenatal assessment of trisomy 21 by
246		multiplexed maternal plasma DNA sequencing: large scale validity
247		study. BMJ 2011;342: c7401.
248	14	Ehrich M, Deciu C, et al. Noninvasive detection of fetal trisomy 21 by sequencing of
249		DNA in maternal blood: a study in a clinical setting. Am J Obstet
250		Gynecol 2011;204: 205 e1– 11.
251	15	Palomaki GE, Kloza EM, et al. DNA sequencing of maternal plasma to detect Down
252		syndrome: an international clinical validation study. Genet Med 2011;13: 913-20.

Page **13** of **19**

253	16. Sehnert AJ, Rhees B, et al. Optimal detection of fetal chromosomal abnormalities by
254	massively parallel DNA sequencing of cell free fetal DNA from maternal
255	blood. Clin Chem 2011;57: 1042–9.

- 256 17. Sparks AB, Struble CA, et al. Non□invasive prenatal detection and selective analysis
 257 of cell□free DNA obtained from maternal blood: evaluation for trisomy 21 and
 258 trisomy 18. Am J Obstet Gynecol 2012;206: 319.e1– 9.
- 259 18. Ashoor G, Syngelaki A, et al. Chromosome selective sequencing of maternal plasma
 260 cell free DNA for first trimester detection of trisomy 21 and trisomy 18. Am J
 261 Obstet Gynecol 2012;206: 322.e1-5.
- 19. Norton ME, Brar H, et al. Non□Invasive Chromosomal Evaluation (NICE) Study:
 results of a multicenter prospective cohort study for detection of fetal trisomy 21 and
 trisomy 18. Am J Obstet Gynecol 2012;207: 137.e1– 8.
- 265 20. Bianchi DW, Platt LD, et al. Genome □ wide fetal aneuploidy detection by maternal
 266 plasma DNA sequencing. Obstet Gynecol 2012;119: 890–901.
- 267 21. Nicolaides KH, Syngelaki A, et al. Noninvasive prenatal testing for fetal trisomies in
 268 a routinely screened first □ trimester population. Am J Obstet Gynecol 2012;207:
 269 374.e1-6.
- 270 22. Rousseau F, Langlois S, et al. Prospective head-to-head comparison of accuracy of
 271 two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the
 272 PEGASUS study. Eur J Hum Genet. 2019;27: 1701–1715.
- 273 23. Gregg AR, Skotko BG, et al. Noninvasive prenatal screening for fetal aneuploidy,
 274 2016 update: a position statement of the American College of Medical Genetics and
- 275 Genomics. Genet Med. 2016 Oct;18(10): 1056-65.

Page **14** of **19**

276	24.	Chetty S, Garabedian MJ, et al. Uptake of noninvasive prenatal testing (NIPT) in
277		women following positive aneuploidy screening. Prenat Diagn. 2013 Jun;33(6): 542-
278		6.
279	25.	Srebniak MI, Diderich KE, et al. Abnormal non-invasive prenatal test results
280		concordant with karyotype of cytotrophoblast but not reflecting abnormal fetal
281		karyotype. Ultrasound Obstet. Gynecol. 2014;44: 109–111.
282	26.	Grati FR, Malvestiti F, et al. Fetoplacental mosaicism: Potential implications for
283		false-positive and false-negative noninvasive prenatal screening results. Genet. Med.
284		2014;16: 620–624.
285	27.	Hall AL, Drendel HM, et al. Positive cell-free fetal DNA testing for trisomy 13
286		reveals confined placental mosaicism. Genet. Med. 2013;15: 729-732.
287	28.	Grömminger S, Yagmur E, et al. Fetal Aneuploidy Detection by Cell-Free DNA
288		Sequencing for Multiple Pregnancies and Quality Issues with Vanishing Twins. J.
289		Clin. Med. 2014;3: 679–692.
290	29.	Curnow KJ, Wilkins-Haug L, et al. Detection of triploid, molar, and vanishing twin
291		pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test.
292		Am. J. Obstet Gynecol. 2015;212: 79.e1-9.
293	30.	Osborne CM, Hardisty E, et al. Discordant noninvasive prenatal testing results in a
294		patient subsequently diagnosed with metastatic disease. Prenat Diagn. 2013 Jun;33(6):
295		609-11. doi: 10.1002/pd.4100.
296	31.	Yao H, Zhang L, et al. Noninvasive prenatal genetic testing for fetal aneuploidy
297		detects maternal trisomy X. Prenat. Diagn. 2012; 32: 1114–1116.
298	32.	Hartwig TS, Ambye L, et al. Discordant non-invasive prenatal testing (NIPT)-A
299		systematic review. Prenat. Diagn. 2017;37: 527-539.

Page **15** of **19**

300	33.	Wang J, Wang ZW, et al. Lower detectability of non-invasive prenatal testing
301		compared to prenatal diagnosis in high-risk pregnant women. Ann Transl Med.
302		2019;7(14): 319.
303	34.	VeriSeq NIPT Solution Package Insert (100000001856 v07) (illumina.com) [Cited
304		05/20/21] Available from: <u>https://support.illumina.com/content/dam/illumina-</u>
305		support/documents/documentation/chemistry_documentation/dx/veriseq-nipt-
306		solution/veriseq-nipt-sample-prep-package-insert-ceivd-1000000001856-07.pdf
307	35.	Hancock S, Ben-Shachar R, et al. Clinical experience across the fetal-fraction
308		spectrum of a non-invasive prenatal screening approach with low test-failure rate.
309		Ultrasound Obstet Gynecol 2020;56: 422-430

310 36. Palomak, G., Deciu C., et al. DNA sequencing of maternal plasma reliably identifies
311 trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative
312 study. Genet Med 2012;14: 296–305

Page **16** of **19**

Table one: Test performance Vanadis[®] NIPT – Aneuploidy (Sweden+Malaysia+USA)

	Trisomy 21	Trisomy 18	Trisomy 13
Total subjects	408+214+234=856	408+214+234=856	408+214+234=856
No calls:	8 (no call r	ate: 0.93%, with unrepeated	samples)
Without no calls:	848	848	848
True positives †	7(5)+4(0)+8(4)=19	7(6)+2(0)+2(2)=11	6(6)+1(0)+2(2)=9
False positives	2+0+0=2	4+0+0=4	1+0+1=2
True negatives	827	833	837
False negatives	0	0	0
Sensitivity (95% CI)	100.00% (82.35% to 100.00%)	100.00% (71.51% to 100.00%)	100.00% (66.37% to 100.00%)
Specificity (95% CI)	99.76% (99.13% to 99.97%)	99.52% (98.78% to 99.87%)	99.76% (99.14% to 99.97%)

315

†25 out of 39 are SeraCare samples; SeraCare samples are within parentheses

Page **17** of **19**

Table two: Test performance Vanadis[®] NIPT – Sex classification

Sv	veden		Malaysia			USA		
391			214			234		
	Females	Males		Females	Males		Females	Males
Total subjects	166	225	Total subjects	94	120	Total subjects	101	133
No calls	6		No calls	2		No calls	0	
Total subjects (w/o no calls)	164	221	Total subjects (w/o no calls)	92	120	Total subjects (w/o no calls)	101	133
Correct classification	162	220	Correct classification	92	120	Correct classification	98	129
Incorrect classification	2	1	Incorrect classification	0	0	Incorrect classification	3	4
	Females	Males	TOTAL	Performance Criteria	Females	Males	TOT	AL
Total subjects	361	478	839	Accuracy	98.79%	98.79%	98.79	9%
No calls excluded:	357	474	831		I	I	I	
Correct classification	352	469	821					
Incorrect classification	5	5	10					

Page **18** of **19**

Table three: Comparison of Next-Generation Sequencing NIPT vs Vanadis[®] NIPT

	NGS NIPT ^{5,15,22,34-36}	Vanadis ^{8,*}
No call results	0.7 - 6.6%	0.1-0.9%
Sensitivity (21)	98.6->99.9%	>99.9%
Sensitivity (18)	90 - >99.9%	89 - >99.9%
Sensitivity (13)	91.7 ->99.9%	>99.9%
Specificity (21)	99.5 - 99.9%	99.8 ->99.9%
Specificity (18)	99.7 - >99.9%	99.5%
Specificity (13)	99.0 - 99.8%	99.8 ->99.9%

320 *Including this study

Page **19** of **19**

322 Characteristics of Study Subjects:

Characteristic	Values
Euploid subjects	817
T21 samples	19 (10 pregnant samples, 9 reference materials)
T18 samples	11 (3 pregnant sample, 8 reference materials)
T13 samples	9 (1 pregnant sample, 8 reference materials)
Maternal age, median (min-max)	32 (20years-46years)
Gestational age, median (min-max)	12weeks 5days (10weeks-34weeks)
First pass no calls	8

323 Figure 1

324